Search

Your search keyword '"Mishra, Asmita"' showing total 602 results
Start Over Author "Mishra, Asmita"
602 results on '"Mishra, Asmita"'

52. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis

Author

Khimani, Farhad, Dutta, Mudit, Faramand, Rawan, Nishihori, Taiga, Perez, Ariel Perez, Dean, Erin, Nieder, Michael, Perez, Lia, Mishra, Asmita, Elmariah, Hany, Davila, Marco, Ochoa, Leonel, Alsina, Melissa, Lazaryan, Aleksandr, Bejanyan, Nelli, Hansen, Doris, Jain, Michael, Locke, Frederick, Liu, Hien, Pidala, Joseph, Shah, Bijal, and Mhaskar, Rahul

Published
2021
Full Text
View/download PDF

53. Breaking the Age Barrier: Physicians’ Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults

Author

Mishra, Asmita, Preussler, Jaime M., Bhatt, Vijaya Raj, Bredeson, Christopher, Chhabra, Saurabh, D'Souza, Anita, Dahi, Parastoo B., Hacker, Eileen Danaher, Gowda, Lohith, Hashmi, Shahrukh K., Howard, Dianna S., Jakubowski, Ann, Jayani, Reena, Koll, Thuy, Lin, Richard J., Olin, Rebecca L., Popat, Uday R., Rodriguez, Cesar, Rosko, Ashley, Sabloff, Mitchell, Sorror, Mohamed L., Sung, Anthony D., Ustun, Celalettin, Wood, William A., Burns, Linda, and Artz, Andrew

Published
2021
Full Text
View/download PDF

56. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Author

Hansen, Doris K., Kim, Jongphil, Thompson, Zachary, Hussaini, Mohammad, Nishihori, Taiga, Ahmad, Anam, Elmariah, Hany, Faramand, Rawan, Mishra, Asmita, Davila, Marco L., Khimani, Farhad, Lazaryan, Aleksandr, Sallman, David, Liu, Hien, Perez, Lia E., Fernandez, Hugo, Nieder, Michael L., Lancet, Jeffrey E., Pidala, Joseph A., Anasetti, Claudio, and Bejanyan, Nelli

Published
2021
Full Text
View/download PDF

57. Figure S1 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Faramand, Rawan, primary, Jain, Michael, primary, Staedtke, Verena, primary, Kotani, Hiroshi, primary, Bai, Renyuan, primary, Reid, Kayla, primary, Lee, Sae Bom, primary, Spitler, Kristen, primary, Wang, Xuefeng, primary, Cao, Biwei, primary, Pinilla, Javier, primary, Lazaryan, Aleksander, primary, Khimani, Farhad, primary, Shah, Bijal, primary, Chavez, Julio C., primary, Nishihori, Taiga, primary, Mishra, Asmita, primary, Mullinax, John, primary, Gonzalez, Ricardo, primary, Hussaini, Mohammad, primary, Dam, Marian, primary, Brandjes, Brigett D., primary, Bachmeier, Christina A., primary, Anasetti, Claudio, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2023
Full Text
View/download PDF

58. Supplementary Table 8 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

59. Supplementary Table 2 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

60. Supplementary Figure 3 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

61. Supplementary Figure 2 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

62. Supplementary Table 3 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

63. Supplementary Table 4 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

64. Supplementary Figure 1 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

65. Extended Methods from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

66. Supplementary Figure 6 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

67. Supplementary Table 7 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

68. Supplementary Table 5 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

69. Supplementary Table 1 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

70. Supplementary Table 6 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

71. Supplementary Figure 4 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

72. Supplementary Figure 5 from Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Author

Pidala, Joseph, primary, Walton, Kelly, primary, Elmariah, Hany, primary, Kim, Jongphil, primary, Mishra, Asmita, primary, Bejanyan, Nelli, primary, Nishihori, Taiga, primary, Khimani, Farhad, primary, Perez, Lia, primary, Faramand, Rawan G., primary, Davila, Marco L., primary, Nieder, Michael L., primary, Sagatys, Elizabeth M., primary, Holtan, Shernan G., primary, Lawrence, Nicholas J., primary, Lawrence, Harshani R., primary, Blazar, Bruce R., primary, Anasetti, Claudio, primary, Sebti, Said M., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

73. Tables S1-S4 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Faramand, Rawan, primary, Jain, Michael, primary, Staedtke, Verena, primary, Kotani, Hiroshi, primary, Bai, Renyuan, primary, Reid, Kayla, primary, Lee, Sae Bom, primary, Spitler, Kristen, primary, Wang, Xuefeng, primary, Cao, Biwei, primary, Pinilla, Javier, primary, Lazaryan, Aleksander, primary, Khimani, Farhad, primary, Shah, Bijal, primary, Chavez, Julio C., primary, Nishihori, Taiga, primary, Mishra, Asmita, primary, Mullinax, John, primary, Gonzalez, Ricardo, primary, Hussaini, Mohammad, primary, Dam, Marian, primary, Brandjes, Brigett D., primary, Bachmeier, Christina A., primary, Anasetti, Claudio, primary, Locke, Frederick L., primary, and Davila, Marco L., primary

Published
2023
Full Text
View/download PDF

74. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups:Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study

Author

Versluis, Jurjen, Saber, Wael, Tsai, Harrison K., Gibson, Christopher J., Dillon, Laura W., Mishra, Asmita, McGuirk, Joseph, Maziarz, Richard T., Westervelt, Peter, Hegde, Pranay, Mukherjee, Devdeep, Martens, Michael J., Logan, Brent, Horowitz, Mary, Hourigan, Christopher S., Nakamura, Ryotaro, Cutler, Corey, Lindsley, R. Coleman, Versluis, Jurjen, Saber, Wael, Tsai, Harrison K., Gibson, Christopher J., Dillon, Laura W., Mishra, Asmita, McGuirk, Joseph, Maziarz, Richard T., Westervelt, Peter, Hegde, Pranay, Mukherjee, Devdeep, Martens, Michael J., Logan, Brent, Horowitz, Mary, Hourigan, Christopher S., Nakamura, Ryotaro, Cutler, Corey, and Lindsley, R. Coleman

Abstract

PURPOSE:Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study.METHODS:We performed targeted sequencing in 309 patients age 50-75 years with International Prognostic Scoring System (IPSS) intermediate-2 or high-risk MDS, enrolled in the Blood and Marrow Transplant Clinical Trials Network 1102 study and assessed the association of gene mutations with OS. Patients with TP53 mutations were classified as TP53multihit if two alleles were altered (via point mutation, deletion, or copy-neutral loss of heterozygosity).RESULTS:The distribution of gene mutations was similar in the donor and no donor arms, with TP53 (28% v 29%; P =.89), ASXL1 (23% v 29%; P =.37), and SRSF2 (16% v 16%; P =.99) being most common. OS in patients with a TP53 mutation was worse compared with patients without TP53 mutation (21% ± 5% [SE] v 52% ± 4% at 3 years; P <.001). Among those with a TP53 mutation, OS was similar between TP53single versus TP53multihit (22% ± 8% v 20% ± 6% at 3 years; P =.31). Considering HCT as a time-dependent covariate, patients with a TP53 mutation who underwent HCT had improved OS compared with non-HCT treatment (OS at 3 years: 23% ± 7% v 11% ± 7%; P =.04), associated with a hazard ratio of 3.89; 95% CI, 1.87 to 8.12; P <.001 after adjustment for covariates. OS among patients with molecular IPSS (IPSS-M) very high risk without a TP53 mutation was significantly improved if they had a donor (68% ± 10% v 0% ± 12% at 3 years; P =.001).CONCLUSION:HCT improved OS compared with non-HCT treatment in patients with TP53 mutations irrespective of TP53 allelic status. Patients with IPSS-M very high risk without a TP53 mutation had favorable outcomes when a donor was available.

Published
2023

75. Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients

Author

Mishra, Asmita, Pidala, Joseph, Thapa, Ram, Betts, Brian C., Fernandez, Hugo, Locke, Frederick L., Nishihori, Taiga, Perez, Lia, Wang, Xuefeng, Anasetti, Claudio, and Jim, Heather

Abstract

We conducted a prospective study of adult allogeneic hematopoietic cell transplantation (HCT) recipients to assess pre- and post-HCT physical function. Baseline measurements included a wrist actigraphy, a 6 min walk test (6MWT), an international physical activity questionnaire (IPAQ), and a Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) as well as serial post-HCT assessments of 6MWT, IPAQ, and FACT-BMT. Forty-seven patients were evaluable for functionality assessments, with a median follow-up of 54.5 months for surviving recipients. No patients demonstrated vigorous or very vigorous activity at any time during monitoring by wrist actigraphy; patients spent a median of 6 h daily sedentary. Self-reported activity via the IPAQ showed 36%, 43%, and 21% of subjects reporting light, moderate, and vigorous activity prior to HCT, respectively. Post-HCT 6MWTs on day +30 demonstrated the greatest association with subsequent survival and non-relapse mortality. A decline in 6MWT distance over time also demonstrated worsened overall survival. This study shows the feasibility of fitness assessments and the ability to risk stratify for subsequent mortality, particularly using the 6MWT on the day +30 single time point assessment and change scores from baseline to day +30 post HCT. These pilot findings suggest important targets for future study.

Published
2024
Full Text
View/download PDF

76. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.

Author

Versluis, Jurjen, Saber, Wael, Tsai, Harrison K., Gibson, Christopher J., Dillon, Laura W., Mishra, Asmita, McGuirk, Joseph, Maziarz, Richard T., Westervelt, Peter, Hegde, Pranay, Mukherjee, Devdeep, Martens, Michael J., Logan, Brent, Horowitz, Mary, Hourigan, Christopher S., Nakamura, Ryotaro, Cutler, Corey, and Lindsley, R. Coleman

Published
2023
Full Text
View/download PDF

77. A comprehensive thermo-kinetics devolatilization analysis of waste motor oil: Thermal degradation kinetics, kinetic model, thermodynamic analysis, and ANN.

Author

Mishra, Asmita, Sonowal, Mayuri, Turlapati, Venkata Yasaswy, Maiti, Payal, and Meikap, B.C.

Subjects
PETROLEUM waste, LUBRICATING oils, ORGANIC wastes, ACTIVATION energy, WASTE management
Abstract

The improper management of waste motor oil (WMO) disturbs the ecology. However, WMO is a potential feedstock for alternate energy production employing the pyrolysis technique. The present study presents the feasibility of WMO pyrolysis in sustainable alternate energy generation. Five different models, namely Flynn-Wall-Ozawa (FWO) and Starink, Coats-Redfern, consecutive reaction model (CRM), and distributed activation energy model (DAEM), were applied for the assessment of the thermo-kinetic parameters of WMO pyrolysis using the thermogravimetric analysis at three discrete heating rates (5, 10, and 40 ºC min−1). The thermogravimetric experimental data of WMO pyrolysis is validated by the artificial neural network (ANN). The average activation energy of WMO for FWO (140.7 kJ mol−1), Starink (143.6 kJ mol−1), Coats-Redfern (116.08 kJ mol−1), CRM (123.22 kJ mol−1), and DAEM (110 kJ mol−1) are lower than conventional organic wastes and hence beneficial for the co-pyrolysis process. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

78. Impact of Obesity and Chemotherapy Dosing on Allogeneic Hematopoietic Cell Transplant Outcomes for Myelodysplastic Syndrome (MDS)

Author

Albanyan, Omar, primary, Naqvi, Syeda Mahrukh, additional, Mo, Qianxing, additional, Belfon, Athena, additional, Gaskill, Eric, additional, Nishihori, Taiga, additional, Faramand, Rawan G, additional, Lazaryan, Aleksandr, additional, Hansen, Doris K, additional, Khimani, Farhad, additional, Mishra, Asmita, additional, Nieder, Dr. Michael L., additional, Perez, Lia Elena, additional, Liu, Hien, additional, Pidala, Joseph A., additional, Anasetti, Claudio, additional, Locke, Frederick L., additional, Bejanyan, Nelli, additional, and Elmariah, Hany, additional

Published
2023
Full Text
View/download PDF

79. Developing Contemporary Survivorship Clinic for Recipients of Hematopoietic Cell Transplantation: A Single Center Experience

Author

Mohty, Razan, primary, Nishihori, Taiga, additional, Faramand, Rawan G, additional, Hansen, Doris K, additional, Nieder, Dr. Michael L., additional, Lazaryan, Aleksandr, additional, Besaw, Laura, additional, Smith, Meredith Tate, additional, Rowe, Jolene, additional, Mishra, Asmita, additional, Pidala, Joseph A., additional, Bejanyan, Nelli, additional, Alsina, Melissa, additional, Khimani, Farhad, additional, Puglianini, Omar Castaneda, additional, Perez, Lia Elena, additional, Elmariah, Hany, additional, Jain, Michael D, additional, Ochoa-Bayona, Jose Leonel, additional, Locke, Frederick L., additional, and Liu, Hien, additional

Published
2023
Full Text
View/download PDF

80. Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Author

Elmariah, Hany, primary, Kim, Jongphil, additional, Reid, Kayla, additional, Cubitt, Christopher, additional, Lancet, Jeffrey E, additional, Kuykendall, Andrew T, additional, Komrokji, Rami, additional, Sallman, David, additional, Chan, Onyee, additional, Sweet, Kendra, additional, Ribickas, Albert, additional, Faramand, Rawan G, additional, Mishra, Asmita, additional, Khimani, Farhad, additional, Perez, Lia Elena, additional, Kirtane, Kedar, additional, Dormesy, Stephanie, additional, Kessler, Debra, additional, Hansen, Doris K, additional, Pidala, Joseph A., additional, Anasetti, Claudio, additional, Fuchs, Ephraim J., additional, Jain, Michael D, additional, Locke, Frederick L., additional, Bejanyan, Nelli, additional, and DeZern, Amy E., additional

Published
2023
Full Text
View/download PDF

81. The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide

Author

Elmariah, Hany, primary, Otoukesh, Salman, additional, Kumar, Ambuj, additional, Gonzalez, Rebecca, additional, DiMaggio, Elizabeth, additional, Ali, Haris, additional, Arslan, Shukaib, additional, Desai, Amrita, additional, Blackmon, Amanda, additional, Nishihori, Taiga, additional, Faramand, Rawan G, additional, Mishra, Asmita, additional, Khimani, Farhad, additional, Fernandez, Hugo F, additional, Lazaryan, Aleksandr, additional, Nieder, Dr. Michael L., additional, Perez, Lia Elena, additional, Liu, Hien, additional, Nakamura, Ryotaro, additional, Pidala, Joseph A., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Anasetti, Claudio, additional, Locke, Frederick L., additional, Bejanyan, Nelli, additional, and Al Malki, Monzr M., additional

Published
2023
Full Text
View/download PDF

82. Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Author

Ionescu, Filip, primary, Ajayi, Eloho, additional, Leach, Aamia, additional, Alsina, Melissa, additional, Bejanyan, Nelli, additional, Castaneda, Omar, additional, Elmariah, Hany, additional, Freeman, Ciara, additional, Hansen, Doris K, additional, Jain, Michael D, additional, Khimani, Farhad, additional, Lazaryan, Aleksandr, additional, Liu, Hien, additional, Locke, Frederick L., additional, Mishra, Asmita, additional, Nieder, Dr. Michael L., additional, Ochoa, Leonel, additional, Perez, Lia Elena, additional, Pidala, Joseph A., additional, Quilitz, Rod, additional, Klinkova, Olga V, additional, Baluch, Aliyah, additional, Nishihori, Taiga, additional, and Faramand, Rawan G, additional

Published
2023
Full Text
View/download PDF

86. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes

Author

Mishra, Asmita, primary, Tamari, Roni, additional, DeZern, Amy E., additional, Byrne, Michael T., additional, Gooptu, Mahasweta, additional, Chen, Yi-Bin, additional, Deeg, H. Joachim, additional, Sallman, David, additional, Gallacher, Phillip, additional, Wennborg, Anders, additional, Hickman, Denice K., additional, Attar, Eyal C., additional, and Fernandez, Hugo F., additional

Published
2022
Full Text
View/download PDF

87. Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Author

Sallman, David A., primary, Elmariah, Hany, additional, Sweet, Kendra, additional, Mishra, Asmita, additional, Cox, Cheryl A, additional, Chakaith, Marion, additional, Semnani, Roshanak, additional, Shehzad, Sheeba, additional, Anderson, Asha, additional, Sabzevari, Helen, additional, Lankford, Amy, additional, Chan, Onyee, additional, SanchezMolina, Luis, additional, Wang, Chen, additional, Padron, Eric, additional, Kuykendall, Andrew, additional, Komrokji, Rami S., additional, Lancet, Jeffrey E., additional, Davila, Marco L., additional, and Bejanyan, Nelli, additional

Published
2022
Full Text
View/download PDF

88. Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Author

Albanyan, Omar, primary, Naqvi, Syeda Mahrukh Hussnain, additional, Mo, Qianxing, additional, Belfon, Athena, additional, Gaskill, Eric, additional, Nishihori, Taiga, additional, Faramand, Rawan, additional, Lazaryan, Aleksandr, additional, Hansen, Doris K., additional, Khimani, Farhad, additional, Mishra, Asmita, additional, Nieder, Michael, additional, Perez, Lia, additional, Liu, Hien D., additional, Pidala, Joseph, additional, Anasetti, Claudio, additional, Locke, Frederick L., additional, Bejanyan, Nelli, additional, and Elmariah, Hany, additional

Published
2022
Full Text
View/download PDF

89. Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Author

Parker, Nathan, primary, Modi, Karnav, additional, Villanueva, Ricardo, additional, Skelson, Lawrence, additional, Scotto, Ashley, additional, Booth-Jones, Margaret, additional, De Avila, Gabriel, additional, Jain, Michael D., additional, Mishra, Asmita, additional, Faramand, Rawan, additional, Akhtar, Othman Salim, additional, Brayer, Jason, additional, Castaneda-Puglianini, Omar, additional, Grajales-Cruz, Ariel F., additional, Baz, Rachid C., additional, Blue, Brandon J., additional, Shain, Kenneth H., additional, Alsina, Melissa, additional, Liu, Hien D., additional, Nishihori, Taiga, additional, Locke, Frederick L., additional, Hansen, Doris K., additional, and Freeman, Ciara L., additional

Published
2022
Full Text
View/download PDF

90. Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Author

Elmariah, Hany, primary, Otoukesh, Salman, additional, Kumar, Ambuj, additional, Ali, Haris, additional, Arslan, Shukaib, additional, Desai, Amrita, additional, Blackmon, Amanda, additional, Pourhassan, Hoda, additional, Nishihori, Taiga, additional, Faramand, Rawan, additional, Mishra, Asmita, additional, Khimani, Farhad, additional, Fernandez, Hugo F, additional, Lazaryan, Aleksandr, additional, Nieder, Michael, additional, Perez, Lia, additional, Liu, Hien D., additional, Nakamura, Ryotaro, additional, Pidala, Joseph, additional, Marcucci, Guido, additional, Forman, Stephen J, additional, Anasetti, Claudio, additional, Locke, Frederick L., additional, Bejanyan, Nelli, additional, and Al Malki, Monzr M., additional

Published
2022
Full Text
View/download PDF

91. Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Author

Elmariah, Hany, primary, Kim, Jongphil, additional, Reid, Kayla M., additional, Cubitt, Christopher, additional, Kuykendall, Andrew, additional, Lancet, Jeffrey E., additional, Komrokji, Rami S., additional, Sallman, David A., additional, Chan, Onyee, additional, Sweet, Kendra, additional, Ribickas, Albert J, additional, Faramand, Rawan, additional, Mishra, Asmita, additional, Khimani, Farhad, additional, Perez, Lia, additional, Kessler, Debra, additional, Dormesy, Stephanie, additional, Pidala, Joseph, additional, Anasetti, Claudio, additional, Fuchs, Ephraim J., additional, Jain, Michael D., additional, Locke, Frederick L., additional, Davila, Marco L., additional, Bejanyan, Nelli, additional, and DeZern, Amy E., additional

Published
2022
Full Text
View/download PDF

92. Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Author

Ionescu, Filip, primary, Ajayi, Eloho, additional, Leach, Aamia, additional, Alsina, Melissa, additional, Bejanyan, Nelli, additional, Castaneda-Puglianini, Omar, additional, Elmariah, Hany, additional, Freeman, Ciara L., additional, Hansen, Doris K., additional, Jain, Michael D., additional, Khimani, Farhad, additional, Lazaryan, Aleksandr, additional, Liu, Hien D., additional, Locke, Frederick L., additional, McIver, Bryan, additional, Mishra, Asmita, additional, Nieder, Michael, additional, Ochoa, Jose, additional, Perez, Lia, additional, Pidala, Joseph, additional, Baluch, Aliyah, additional, Klinkova, Olga, additional, Quilitz, Rod, additional, Nishihori, Taiga, additional, and Faramand, Rawan, additional

Published
2022
Full Text
View/download PDF

93. Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Author

Ionescu, Filip, primary, Sallman, David A., additional, Sweet, Kendra, additional, Komrokji, Rami S., additional, Chan, Onyee, additional, Kuykendall, Andrew, additional, Padron, Eric, additional, Faramand, Rawan, additional, Bejanyan, Nelli, additional, Khimani, Farhad, additional, Elmariah, Hany, additional, Pidala, Joseph, additional, Mishra, Asmita, additional, Perez, Lia, additional, Nishihori, Taiga, additional, and Lancet, Jeffrey E., additional

Published
2022
Full Text
View/download PDF

94. Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351

Author

Jain, Akriti G, primary, Ball, Somedeb, additional, Aguirre, Luis E.E., additional, Kuykendall, Andrew, additional, Chan, Onyee, additional, Komrokji, Rami S., additional, Padron, Eric, additional, Sallman, David A., additional, Lancet, Jeffrey E., additional, Mishra, Asmita, additional, and Sweet, Kendra, additional

Published
2022
Full Text
View/download PDF

97. Successful management of central nervous system manifestations of chronic graft-vs-host disease: a case report.

Author

Kundalia, Ronak, Hanini, Anas, Kareem, Syeda Saba, Gonzalez, Rebecca, Gatewood, Tyra, Mishra, Asmita, Pina, Yolanda, and Mokhtari, Sepideh

Subjects
CENTRAL nervous system, EPILEPSY, REPORTING of diseases, SARCOIDOSIS, GRAFT versus host disease, MENTAL illness
Abstract

Ensuing MRIs of the brain conducted every 6 months post-IVIG therapy showed no evidence of GVHD to the brain nor of any leukocytic involvement, and a liver biopsy conducted 2364 days post alloHCT was negative for GVHD. Keywords: Graft vs host disease; alloHCT; CNS-GVHD; cerebral vasculitis; intravenous globulin; ibrutinib EN Graft vs host disease alloHCT CNS-GVHD cerebral vasculitis intravenous globulin ibrutinib 1485 1489 5 08/16/23 20230715 NES 230715 Chronic graft-vs-host disease (cGVHD) is an immune-mediated complication that manifests in roughly 40% of patients post allogeneic hematopoietic cell transplantation (alloHCT) [[1]]. Patient was diagnosed with acute-mild GVHD on day + 125 post alloHCT with CNS-cGVHD symptoms first appearing on day + 629 post alloHCT. Certain diagnostic criteria must be met for accurate CNS-cGVHD diagnosis: 1) GVHD involving different organ systems; 2) CNS symptoms with no other explanation; 3) Abnormal brain MRI; 4) positive pathological/postmortem examination; 5) positive CSF study; and 6) positive response to immunosuppression (IS). [Extracted from the article]

Published
2023
Full Text
View/download PDF

98. Ovarian cancer: Age, prognosis, and biologic underpinnings.

Author

Extermann, Martine, primary, Cao, Biwei, additional, Berglund, Anders E., additional, Chern, Jing-Yi, additional, Chon, Hye Sook, additional, Cristea, Mihaela C., additional, Cubitt, Christopher, additional, Gomes, Ana Patricia, additional, Hoffman, Mitchell S, additional, Kim, Jongphil, additional, Marchion, Douglas C., additional, Mishra, Asmita, additional, Sansil, Samer, additional, Sehovic, Marina, additional, Shahzad, Mian M., additional, Walko, Christine Marie, additional, Welsh, Eric, additional, and Zhang, Yonghong, additional

Published
2022
Full Text
View/download PDF

99. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma

Author

Logue, Jennifer, primary, Peres, Lauren, additional, Shrewsbury, Alexandria M, additional, Provencher, Jessica, additional, Nishihori, Taiga, additional, Liu, Hien, additional, Brayer, Jason, additional, Castaneda, Omar, additional, Blue, Brandon Jamaal, additional, Ochoa-Bayona, J. Leonel, additional, Freeman, Ciara, additional, Elmariah, Hany, additional, Faramand, Rawan G, additional, Jain, Michael D, additional, Lazaryan, Aleksandr, additional, Bejanyan, Nelli, additional, Perez, Lia Elena, additional, Nieder, Michael L., additional, Mishra, Asmita, additional, Pidala, Joseph A., additional, Davila, Marco L., additional, Shain, Kenneth, additional, Baz, Rachid, additional, Alsina, Melissa, additional, Locke, Frederick L., additional, and Hansen, Doris K, additional

Published
2022
Full Text
View/download PDF

100. A Multi-Center Collaborative Study of Outcomes of TP53-Mutated MDS/AML Patients Following Allogeneic HCT

Author

Byrne, Michael, primary, Kurian, Tony, additional, Patel, Dilan, additional, Tamari, Roni, additional, Hong, Sanghee, additional, Abdelhakim, Haitham, additional, Klein, Victoria, additional, Rojas, Patricio, additional, Madhavan, Raksha, additional, Kent, Andrew, additional, Logan, Aaron C., additional, Lee, Catherine J., additional, Husnain, Muhammad, additional, Manning, Benjamin, additional, Tschernia, Nicholas, additional, Dias, Ajoy, additional, Margalski, Daniel, additional, Goldenson, Benjamin, additional, Byrne, Nathalie D., additional, Chen, Heidi, additional, Petrova-Drus, Kseniya, additional, Sengsayadeth, Salyka, additional, Goodman, Aaron, additional, Howard, Dianna S., additional, Wood, William A., additional, Gill, Saar, additional, Jimenez, Antonio Jimenez, additional, Gutman, Jonathan A., additional, Gowda, Lohith, additional, Metheny III, Leland, additional, Bhatnagar, Bhavana, additional, Hamilton, Betty K., additional, Mishra, Asmita, additional, and Savona, Michael R., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results